Increase in quinolones prescriptions for children (0–10 years old) in Brazil

Our study revealed a concerning rise in quinolone prescriptions for Brazilian children aged 0-10 years, underscoring the imperative for cautious use due to limited safety data and acknowledged risks, such as musculoskeletal damage. Healthcare providers should prioritize safer alternatives when possible, focusing on children`s well-being and combating antimicrobial resistance. Advocacy for prudent prescribing practices and increased awareness is crucial, along with further research to comprehensively understand long-term effects and establish evidence-based guidelines for quinolone use in pediatric populations.